Published in Pediatr Blood Cancer on March 01, 2009
Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annu Rev Pathol (2011) 1.70
Children's Oncology Group's 2013 blueprint for research: bone tumors. Pediatr Blood Cancer (2012) 1.20
Downstream EWS/FLI1 - upstream Ewing's sarcoma. Genome Med (2010) 1.01
Ewing's sarcoma: overcoming the therapeutic plateau. Discov Med (2012) 0.91
Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. Cancer Genet (2012) 0.87
Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor. Clin Cancer Res (2016) 0.83
Copy Number Alterations and Methylation in Ewing's Sarcoma. Sarcoma (2011) 0.82
The first European interdisciplinary ewing sarcoma research summit. Front Oncol (2012) 0.82
New strategies in ewing sarcoma: lost in translation? Clin Cancer Res (2014) 0.81
Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. Oncotarget (2016) 0.81
Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 0.81
Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment. Clin Sarcoma Res (2012) 0.81
Targeted therapies for advanced Ewing sarcoma family of tumors. Cancer Treat Rev (2015) 0.81
Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors. Cancer Res (2016) 0.79
Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma. Sarcoma (2011) 0.78
Low dose cytarabine in patients with relapsed or refractory Ewing sarcoma. Pediatr Blood Cancer (2009) 0.76
Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma. Oncotarget (2016) 0.75
(18)F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma. Sci Rep (2016) 0.75
How do we identify novel treatment for childhood cancer? Pediatr Blood Cancer (2009) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature (1992) 7.68
Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet (1988) 2.42
Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol (2005) 2.33
Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med (2007) 1.82
Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer (2002) 1.60
Designs for group sequential phase II clinical trials. Biometrics (1987) 1.57
Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol (2003) 1.43
Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol (2003) 1.42
Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer (2008) 1.25
Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies. Clin Pharmacokinet (2000) 1.08
Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res (1987) 1.08
Confidence intervals following group sequential tests. Control Clin Trials (1986) 1.06
Insulin-like growth factor-I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell lines. Eur J Cancer (1993) 1.02
Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin. Anticancer Drugs (2006) 0.96
Pharmacokinetic studies of intermediate-to high-dose 1-beta-D-arabinofuranosylcytosine in children with acute leukemia and lymphoma. J Clin Pharmacol (1987) 0.92
Treatment of childhood acute lymphoblastic leukemia with intermediate-dose cytosine arabinoside and adriamycin. Med Pediatr Oncol (1986) 0.91
Toxicity of high-dose cytosine arabinoside in the treatment of advanced childhood tumors resistant to conventional therapy. A Pediatric Oncology Group study. Cancer (1990) 0.85
Chronic health conditions in adult survivors of childhood cancer. N Engl J Med (2006) 19.97
Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (2003) 11.66
BMJ Publishing Group to launch an international campaign to promote academic medicine. BMJ (2003) 11.51
A common open representation of mass spectrometry data and its application to proteomics research. Nat Biotechnol (2004) 11.42
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
Integrative analysis of the Caenorhabditis elegans genome by the modENCODE project. Science (2010) 9.78
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med (2003) 8.48
Scientific literature's open sesame? BMJ (2003) 7.92
Grand challenges in chronic non-communicable diseases. Nature (2007) 7.86
How should we define health? BMJ (2011) 7.82
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34
Closing the digital divide. BMJ (2003) 6.20
No more free lunches. BMJ (2003) 5.70
The GMC: expediency before principle. BMJ (2005) 5.66
Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JAMA (2003) 5.27
FlyMine: an integrated database for Drosophila and Anopheles genomics. Genome Biol (2007) 5.23
Is the NHS getting better or worse? BMJ (2003) 5.04
What errors do peer reviewers detect, and does training improve their ability to detect them? J R Soc Med (2008) 4.92
Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med (2005) 4.92
Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol (2004) 4.63
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell (2006) 4.52
Four futures for scientific and medical publishing. BMJ (2002) 4.51
The functional spectrum of low-frequency coding variation. Genome Biol (2011) 4.42
Take back your mink, take back your pearls. BMJ (2002) 4.36
Open access publishing takes off. BMJ (2004) 4.29
New BMJ policy on economic evaluations. BMJ (2002) 4.27
Effects of training on quality of peer review: randomised controlled trial. BMJ (2004) 4.20
BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res (2003) 4.17
Open letter to the leader of academic medicine. BMJ (2007) 4.06
Five futures for academic medicine. PLoS Med (2005) 3.95
Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci U S A (2005) 3.49
The value of resident presentations at scientific meetings. Laryngoscope (2013) 3.48
Does declaration of competing interests affect readers' perceptions? A randomised trial. BMJ (2002) 3.44
The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell (2003) 3.36
Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial. BMJ (2005) 3.35
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol (2008) 3.34
Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell (2006) 3.29
Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell (2003) 3.23
Socioeconomic development as an intervention against malaria: a systematic review and meta-analysis. Lancet (2013) 3.22
RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature (2007) 3.21
Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol (2003) 3.21
The discomfort of patient power. BMJ (2002) 3.19
Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov (2013) 3.11
Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia (2008) 3.10
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol (2012) 2.96
Perceptions of open access publishing: interviews with journal authors. BMJ (2005) 2.85
Spend (slightly) less on health and more on the arts. BMJ (2002) 2.83
A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell (2007) 2.83
Reed-Elsevier's hypocrisy in selling arms and health. J R Soc Med (2007) 2.82
Is private health care the answer to the health problems of the world's poor? PLoS Med (2008) 2.82
Making progress with competing interests. BMJ (2002) 2.79
Are some diets "mass murder"? BMJ (2014) 2.73
The NHS in the simulator. BMJ (2009) 2.66
A method for high-throughput gene expression signature analysis. Genome Biol (2006) 2.63
Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. Leukemia (2009) 2.58
Too much medicine? BMJ (2002) 2.53
Big publishers cut access to journals in poor countries. Lancet (2011) 2.48
Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol (2012) 2.46
Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol (2009) 2.44
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol (2013) 2.43
The 1000 Genomes Project: data management and community access. Nat Methods (2012) 2.41
Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell (2009) 2.39
Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol (2006) 2.37
Patient safety requires a new way to publish clinical trials. PLoS Clin Trials (2006) 2.35
Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group. J Neurosurg (2006) 2.31
Lapses at the new England journal of medicine. J R Soc Med (2006) 2.22
Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet (2013) 2.21
Research misconduct: the poisoning of the well. J R Soc Med (2006) 2.16
Research misconduct in low- and middle-income countries. PLoS Med (2013) 2.08
Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proc Natl Acad Sci U S A (2008) 2.06
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol (2008) 2.06
Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood (2006) 2.05
Consultant assessment and appraisal: an outline in practice. Clin Radiol (2002) 2.03
A "fussy eater" with renal failure. Lancet (2010) 2.03
Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952. J Clin Oncol (2007) 2.00
Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J Cell Biol (2002) 2.00
Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol (2005) 1.99
The problems and promise of central pathology review: development of a standardized procedure for the Children's Oncology Group. Pediatr Dev Pathol (2007) 1.95
Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol (2007) 1.94
Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group. Semin Oncol (2008) 1.94
Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg (2006) 1.93
Global response to non-communicable disease. BMJ (2011) 1.93
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res (2006) 1.91
A time for global health. BMJ (2002) 1.91
Twenty thousand conversations. BMJ (2002) 1.91
A POEM a week for the BMJ. BMJ (2002) 1.90
Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study. Pediatr Blood Cancer (2006) 1.90
Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics (2008) 1.90
The BMJ: moving on. BMJ (2002) 1.88
Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. Cancer Cell (2013) 1.86
The fallacy of impartiality: competing interest bias in academic publications. J R Soc Med (2009) 1.85
Does the type of competing interest statement affect readers' perceptions of the credibility of research? Randomised trial. BMJ (2004) 1.84
Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med (2007) 1.82
Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J Clin Oncol (2007) 1.81